Sustained Improvement in Clinical Efficacy, Asthma Control, and Quality of Life in Patients With Severe, Oral Corticosteroid (OCS)-Dependent Asthma Treated With Dupilumab: LIBERTY ASTHMA TRAVERSE Study

Mark Gurnell; Christian  Domingo; Klaus F Rabe; Andrew Menzies-Gow; David Price; Guy  Brusselle; Michael E Wechsler; Changming  Xia; Nami  Pandit-Abid; Rebecca Gall; Juby A.  Jacob-Nara; Paul J.  Rowe; Yamo  Deniz; Shahid  Siddiqui

Sustained Improvement in Clinical Efficacy, Asthma Control, and Quality of Life in Patients With Severe, Oral Corticosteroid (OCS)-Dependent Asthma Treated With Dupilumab: LIBERTY ASTHMA TRAVERSE Study

Mark Gurnell, Christian Domingo, Klaus F Rabe, Andrew Menzies-Gow, David Price, Guy Brusselle, Michael E Wechsler, Changming Xia, Nami Pandit-Abid, Rebecca Gall, Juby A. Jacob-Nara, Paul J. Rowe, Yamo Deniz, Shahid Siddiqui

Research output: Contribution to conference › Abstract › peer-review

1 Downloads (Pure)

Original language	English
Publication status	Accepted/In press - 20 May 2022
Event	EAACI HYBRID CONGRESS 2022 - Prague, Czech Republic Duration: 1 Jul 2022 → 3 Jul 2022 https://www.eaaci.org/eaaci-congresses/eaaci-2022

Conference

Conference	EAACI HYBRID CONGRESS 2022
Country/Territory	Czech Republic
City	Prague
Period	1/07/22 → 3/07/22
Internet address	https://www.eaaci.org/eaaci-congresses/eaaci-2022

Bibliographical note

Acknowledgments and funding sources
Research sponsored by Sanofi and Regeneron Pharmaceuticals, Inc. ClinicalTrials.gov Identifiers: NCT02528214 (VENTURE)/NCT02134028 (TRAVERSE). Medical writing/editorial assistance was provided by Nevena Krstić, PhD, of Excerpta Medica, and was funded by Sanofi Genzyme and Regeneron Pharmaceuticals, Inc., according to the Good Publication Practice guideline.

Access to Document

Gurnell_etal_EAACI_Sustained_Improvement_In_AAMAccepted author manuscript, 175 KB

Cite this

Gurnell, M., Domingo, C., Rabe, K. F., Menzies-Gow, A., Price, D., Brusselle, G., Wechsler, M. E., Xia, C., Pandit-Abid, N., Gall, R., Jacob-Nara, J. A., Rowe, P. J., Deniz, Y., & Siddiqui, S. (Accepted/In press). Sustained Improvement in Clinical Efficacy, Asthma Control, and Quality of Life in Patients With Severe, Oral Corticosteroid (OCS)-Dependent Asthma Treated With Dupilumab: LIBERTY ASTHMA TRAVERSE Study. Abstract from EAACI HYBRID CONGRESS 2022, Prague, Czech Republic.

Sustained Improvement in Clinical Efficacy, Asthma Control, and Quality of Life in Patients With Severe, Oral Corticosteroid (OCS)-Dependent Asthma Treated With Dupilumab: LIBERTY ASTHMA TRAVERSE Study. / Gurnell, Mark; Domingo, Christian ; Rabe, Klaus F et al.
2022. Abstract from EAACI HYBRID CONGRESS 2022, Prague, Czech Republic.

Research output: Contribution to conference › Abstract › peer-review

Gurnell, M, Domingo, C, Rabe, KF, Menzies-Gow, A, Price, D, Brusselle, G, Wechsler, ME, Xia, C, Pandit-Abid, N, Gall, R, Jacob-Nara, JA, Rowe, PJ, Deniz, Y & Siddiqui, S 2022, 'Sustained Improvement in Clinical Efficacy, Asthma Control, and Quality of Life in Patients With Severe, Oral Corticosteroid (OCS)-Dependent Asthma Treated With Dupilumab: LIBERTY ASTHMA TRAVERSE Study', EAACI HYBRID CONGRESS 2022, Prague, Czech Republic, 1/07/22 - 3/07/22.

@conference{4a06b9d279d74f1885da7b754d01ee24,

title = "Sustained Improvement in Clinical Efficacy, Asthma Control, and Quality of Life in Patients With Severe, Oral Corticosteroid (OCS)-Dependent Asthma Treated With Dupilumab: LIBERTY ASTHMA TRAVERSE Study",

author = "Mark Gurnell and Christian Domingo and Rabe, {Klaus F} and Andrew Menzies-Gow and David Price and Guy Brusselle and Wechsler, {Michael E} and Changming Xia and Nami Pandit-Abid and Rebecca Gall and Jacob-Nara, {Juby A.} and Rowe, {Paul J.} and Yamo Deniz and Shahid Siddiqui",

note = "Acknowledgments and funding sources Research sponsored by Sanofi and Regeneron Pharmaceuticals, Inc. ClinicalTrials.gov Identifiers: NCT02528214 (VENTURE)/NCT02134028 (TRAVERSE). Medical writing/editorial assistance was provided by Nevena Krsti{\'c}, PhD, of Excerpta Medica, and was funded by Sanofi Genzyme and Regeneron Pharmaceuticals, Inc., according to the Good Publication Practice guideline. ; EAACI HYBRID CONGRESS 2022 ; Conference date: 01-07-2022 Through 03-07-2022",

year = "2022",

month = may,

day = "20",

language = "English",

url = "https://www.eaaci.org/eaaci-congresses/eaaci-2022",

}

TY - CONF

T1 - Sustained Improvement in Clinical Efficacy, Asthma Control, and Quality of Life in Patients With Severe, Oral Corticosteroid (OCS)-Dependent Asthma Treated With Dupilumab

T2 - EAACI HYBRID CONGRESS 2022

AU - Gurnell, Mark

AU - Domingo, Christian

AU - Rabe, Klaus F

AU - Menzies-Gow, Andrew

AU - Price, David

AU - Brusselle, Guy

AU - Wechsler, Michael E

AU - Xia, Changming

AU - Pandit-Abid, Nami

AU - Gall, Rebecca

AU - Jacob-Nara, Juby A.

AU - Rowe, Paul J.

AU - Deniz, Yamo

AU - Siddiqui, Shahid

N1 - Acknowledgments and funding sources Research sponsored by Sanofi and Regeneron Pharmaceuticals, Inc. ClinicalTrials.gov Identifiers: NCT02528214 (VENTURE)/NCT02134028 (TRAVERSE). Medical writing/editorial assistance was provided by Nevena Krstić, PhD, of Excerpta Medica, and was funded by Sanofi Genzyme and Regeneron Pharmaceuticals, Inc., according to the Good Publication Practice guideline.

PY - 2022/5/20

Y1 - 2022/5/20

M3 - Abstract

Y2 - 1 July 2022 through 3 July 2022

ER -